Clinical Trials Logo

Insulinoma clinical trials

View clinical trials related to Insulinoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05034783 Active, not recruiting - Insulinoma Clinical Trials

[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients

Start date: October 1, 2021
Phase: Early Phase 1
Study type: Interventional

Glucagon-like peptide-1 receptor (GLP-1R)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect insulinoma, like the widely studied [68Ga]Ga-NOTA-exendin-4. This pilot study was prospectively designed to evaluate the early dynamic distribution of [68Ga]Ga-HBED-CC-exendin-4, a novel radiopharmaceutical targeting GLP-1R, which was compared with [68Ga]Ga-NOTA-exendin-4 in the same group of insulinoma patients.

NCT ID: NCT02121366 Active, not recruiting - Insulinoma Clinical Trials

EUS-guided Ethanol Ablation of an Insulinoma

EUS
Start date: March 2014
Phase: N/A
Study type: Interventional

The present study aims to evaluate the feasibility, safety and efficacy of EUS-guided ethanol ablation of an insulinoma.

NCT ID: NCT01824875 Active, not recruiting - Insulinoma Clinical Trials

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

Start date: August 8, 2013
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors. Drugs used in chemotherapy, such as temozolomide and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether temozolomide is more effective with or without capecitabine in treating patients with advanced pancreatic neuroendocrine tumors.